department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Kodiak Sciences Inc. ($KOD) · pharmadog

PUBLIC COMPANY

$KODKodiak Sciences Inc.

Palo Alto, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

tarcocimab tedromer

Retinal Vein Occlusion

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Kodiak Sciences Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$KOD

SEC CIK

0001468748

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

$KOD

Active trials

phase3A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKactive not recruitingn=675
phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLErecruitingn=150
phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKrecruitingn=150
phase3A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)active not recruitingn=255
phase3A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)terminatedn=253
phase3A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)terminatedn=459
phase3A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)terminatedn=460
phase3A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.terminatedn=559

more trials →

Data sources

last refreshed 4m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer12,477 sh @ $40.29−$503K↗
Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer12,692 sh @ $39.14−$497K↗
Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer4,231 sh @ $40.88−$173K↗
Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer600 sh @ $41.77−$25K↗

routine RSU / option mechanics (6)

Apr 15, 26option exerciseBORGESON JOHN A. · Chief Financial Officer28,614 sh
Apr 15, 26option exerciseBORGESON JOHN A. · Chief Financial Officer28,614 sh
Apr 2, 26option exerciseBORGESON JOHN A. · Chief Financial Officer30,000 sh
Apr 2, 26option exerciseBORGESON JOHN A. · Chief Financial Officer30,000 sh
Mar 25, 26option exercisePERLROTH VICTOR · Chairman and CEO300,000 sh

Mar 25, 26

option exercise

PERLROTH VICTOR · Chairman and CEO

300,000 sh